A private California biotechnology company has signed a two-year option agreement with Case Western Reserve University and Dartmouth College to advance a novel immunotherapy to treat cancer and infectious diseases.
Mosaic ImmunoEngineering Inc. of Novato, Calif., was granted the exclusive right to license the technology for a novel platform that uses virus-like nanoparticles (VLP) to treat and prevent cancer and infectious diseases in humans and for veterinary use, according to a news release.
The technology, supported by numerous scientific publications and grant funding, has broad potential to treat many types of cancer and has direct application as part of a vaccine platform, which has generated promising data in cancer and infectious diseases — including COVID-19 — through research funded by the National Science Foundation, according to the release.
Click here to read the complete story.
Story excerpt provided by Crain’s Cleveland Business.
Written by Lydia Coutre.
Originally published September 04, 2020.